Search

Displaying results 1791 - 1800 of 4860 in total
  1. Drug

    Valbenazine

    go.drugbank.com/drugs/DB11915
    ApprovedInvestigational

    Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's

  2. Drug

    Lipegfilgrastim

    go.drugbank.com/drugs/DB13200
    Approved

    It aims to reduce the duration of neutropenia and the incidence of febrile neutropenia. … It is used as an alternate to [DB00019] for prophylactic use in cancer patients receiving chemotherapy and at risk for developing chemotherapy-induced neutropenia.

  3. Drug

    Aceclidine

    go.drugbank.com/drugs/DB13262
    Approved

    [A274273] It has also been studied in the treatment of presbyopia, a common age-related vision loss where the crystalline lens hardens and loses elasticity, impairing near vision.

  4. Drug

    D-Serine

    go.drugbank.com/drugs/DB03929
    ApprovedInvestigationalWithdrawn

    It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids. [PubChem]

  5. Drug

    Sevabertinib

    go.drugbank.com/drugs/DB21667
    ApprovedInvestigational

    [L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608]

  6. Drug

    Sapropterin

    go.drugbank.com/drugs/DB00360
    ApprovedInvestigational

    It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of

  7. Drug

    Buprenorphine

    go.drugbank.com/drugs/DB00921
    ApprovedIllicitInvestigationalVet approved

    [A186283,A186292] It is also commonly used as an alternative to [methadone] for the treatment of severe opioid addiction. … Buprenorphine has a number of unique pharmacokinetic and pharmacodynamic properties that make it a preferred agent for the treatment of conditions requiring high doses of strong opioids.

  8. Drug

    Bivalirudin

    go.drugbank.com/drugs/DB00006
    ApprovedInvestigational

    It is administered intravenously. … Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.

    Products: Bivalirudin Accord 250 mg Pulver für ein Konzentrat zur Herstellung einer Injektions-/Infusionslösung
  9. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    [L48236] Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. … [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized

  10. Drug

    Formestane

    go.drugbank.com/drugs/DB08905
    ApprovedWithdrawn

    It is listed as a prohibited substance by the World Anti-Doping Agency for use in athletes. … It is not US FDA approved, and the intramuscular injection form of formestane (Lentaron) which was approved in Europe has been withdrawn.